{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:42:24Z","timestamp":1790991744259,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p>The immune system has a role in neuropathic pain which includes autoimmune mechanisms (e.g., autoantibodies). Clinical studies have identified a number of conditions where neuropathic pain is common and that are associated with autoantibodies targeting antigens within the nervous system. Interestingly sensory symptoms can be relieved with immunotherapies or plasma exchange, suggesting that pain in these patients is antibody-mediated. Recent preclinical studies have directly addressed this. For example, passive transfer of CASPR2 autoantibodies from patients cause increased pain sensitivity and enhanced sensory neuron excitability in mice confirming pathogenicity and demonstrating that patient autoantibodies are a mechanism to cause neuropathic pain. Small fiber neuropathy (SFN) exclusively affects small sensory fibers (typically nociceptors) and is characterized by severe neuropathic pain. Known causes include diabetes, B12 deficiency and rare variants in sodium channel genes, although around 50% of cases are idiopathic. SFN is associated with autoimmune conditions such as Sjorgen\u2019s syndrome, Sarcoidosis and Celiac disease and immunotherapy in the form of Intravenous immunoglobulin (IVIG) has proved an effective treatment. Autoantibodies have been identified and, in some cases, passive transfer of SFN patient IgG in mice can recapitulate neuropathic pain-like behavior. Here we will discuss clinical and preclinical data relating to the idea that pathogenic autoantibodies contribute to SNF. We discuss putative pathogenic antibodies, cellular targets and the molecular mechanisms by which they cause sensory neuron damage and the development of neuropathic pain. Finally, we will comment on future directions which may provide further insights into the mechanisms underlying SFN in patients.<\/jats:p>","DOI":"10.3389\/fnmol.2023.1254854","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T03:20:44Z","timestamp":1695266444000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["A role for pathogenic autoantibodies in small fiber neuropathy?"],"prefix":"10.3389","volume":"16","author":[{"given":"Omar","family":"Daifallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/jnnp-2014-309730","article-title":"Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy.","volume":"86","author":"Antoine","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/ICO.0000000000003142","article-title":"Autoantibodies against trisulfated heparin disaccharide and fibroblast growth factor receptor-3 May play a role in the pathogenesis of neuropathic corneal pain.","volume":"42","author":"Bayraktutar","year":"2022","journal-title":"Cornea"},{"key":"B3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/mus.27340","article-title":"Small fiber neuropathy: Swiss cohort characterization.","volume":"64","author":"Bitzi","year":"2021","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14508","article-title":"Post-endocytic sorting of Plexin-D1 controls signal transduction and development of axonal and vascular circuits.","volume":"8","author":"Burk","year":"2017","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ana.26268","article-title":"Novel autoantibodies in idiopathic small fiber neuropathy.","volume":"91","author":"Chan","year":"2022","journal-title":"Ann. Neurol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain.","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1085-9489.2006.00062.x","article-title":"Acute steroid responsive small-fiber sensory neuropathy: A new entity?","volume":"11","author":"Dabby","year":"2006","journal-title":"J. Peripheral Nervous Syst."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P2.433","article-title":"Use of Intravenous Immunoglobulin in small fiber neuropathy associated with FGFR3 (P2.433).","volume":"90","author":"Dave","year":"2018","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200047","article-title":"Guillain-Barr\u00e9 syndrome following zika virus infection is associated with a diverse spectrum of peripheral nerve reactive antibodies.","volume":"10","author":"Davies","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.neuron.2018.01.033","article-title":"Immune or genetic-mediated disruption of caspr2 causes pain hypersensitivity due to enhanced primary afferent excitability.","volume":"97","author":"Dawes","year":"2018","journal-title":"Neuron"},{"key":"B11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/ene.13508","article-title":"Associated conditions in small fiber neuropathy\u2013a large cohort study and review of the literature.","volume":"25","author":"de Greef","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/14737175.2020.1794825","article-title":"Clinical diagnosis and management of small fiber neuropathy: An update on best practice.","volume":"20","author":"Devigili","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/jnnp-2018-319042","article-title":"Yield of peripheral sodium channels gene screening in pure small fibre neuropathy.","volume":"90","author":"Eijkenboom","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cne.21351","article-title":"Cellular subtype distribution and developmental regulation of TRPC channel members in the mouse dorsal root ganglion.","volume":"503","author":"Elg","year":"2007","journal-title":"J. Comp. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/ane.13591","article-title":"Small fiber neuropathy.","volume":"145","author":"Finsterer","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001028","article-title":"Antiplexin D1 antibodies relate to small fiber neuropathy and induce neuropathic pain in animals.","volume":"8","author":"Fujii","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ana.25279","article-title":"A novel autoantibody against Plexin D1 in patients with neuropathic pain.","volume":"84","author":"Fujii","year":"2018","journal-title":"Ann. Neurol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102387","article-title":"Intravenous immunoglobulin efficacy for primary Sj\u00f6gren\u2019s syndrome associated small fiber neuropathy.","volume":"18","author":"Gaillet","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2534","DOI":"10.1212\/WNL.0000000000012714","article-title":"Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy.","volume":"96","author":"Geerts","year":"2021","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mus.27379","article-title":"Non-length-dependent small fiber neuropathy: Not a matter of stockings and gloves.","volume":"65","author":"Gemignani","year":"2022","journal-title":"Muscle Nerve"},{"key":"B21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.27745","article-title":"A double-blind placebo-controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS-HDS and FGFR-3 autoantibodies.","volume":"67","author":"Gibbons","year":"2023","journal-title":"Muscle Nerve"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144201","article-title":"Passive transfer of fibromyalgia symptoms from patients to mice.","volume":"131","author":"Goebel","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mus.26748","article-title":"Cryptogenic small-fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor-3.","volume":"61","author":"Levine","year":"2020","journal-title":"Muscle Nerve"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201312","article-title":"Follow-up Editors\u2019 note: Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy.","volume":"98","author":"Lewis","year":"2022","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617744484","article-title":"IVIg for apparently autoimmune small-fiber polyneuropathy: First analysis of efficacy and safety.","volume":"11","author":"Liu","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"19393","DOI":"10.1074\/jbc.M500391200","article-title":"MxA, a member of the dynamin superfamily, interacts with the ankyrin-like repeat domain of TRPC.","volume":"280","author":"Lussier","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/CND.0000000000000236","article-title":"Prevalence of axonal sensory neuropathy with IgM binding to trisulfated heparin disaccharide in patients with fibromyalgia.","volume":"20","author":"Malik","year":"2019","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamaneurol.2019.2917","article-title":"Scientific advances in and clinical approaches to small-fiber polyneuropathy: A review.","volume":"76","author":"Oaklander","year":"2019","journal-title":"JAMA Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jca.21944","article-title":"Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients.","volume":"37","author":"Olsen","year":"2022","journal-title":"J. Clin. Apher."},{"key":"B30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mus.10301","article-title":"Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide.","volume":"27","author":"Pestronk","year":"2003","journal-title":"Muscle Nerve"},{"key":"B31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mus.23256","article-title":"Clinical and laboratory features of neuropathies with serum IgM binding to TS-HDS.","volume":"45","author":"Pestronk","year":"2012","journal-title":"Muscle Nerve"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a8236e","article-title":"Incidence and prevalence of small-fiber neuropathy: A survey in the Netherlands.","volume":"81","author":"Peters","year":"2013","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s00415-020-10033-z","article-title":"Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sj\u00f6gren\u2019s syndrome.","volume":"267","author":"Pindi Sala","year":"2020","journal-title":"J. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1111\/jns.12570","article-title":"The autoimmune vulnerability of the node of Ranvier.","volume":"28","author":"Querol","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.26189","article-title":"Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: Clinical and biological comparisons.","volume":"90","author":"Ramanathan","year":"2021","journal-title":"Ann. Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CND.0000000000000221","article-title":"FGFR3 antibodies in neuropathy: What to do with them?","volume":"20","author":"Samara","year":"2018","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1016\/j.vaccine.2009.09.077","article-title":"Small fiber neuropathy following vaccination for rabies, varicella or Lyme disease.","volume":"27","author":"Souayah","year":"2009","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/j.1468-1331.2008.02305.x","article-title":"Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease.","volume":"15","author":"Souayah","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4872-09.2010","article-title":"ERK1\/2 Mitogen-activated protein kinase phosphorylates sodium channel Nav1.7 and alters its gating properties.","volume":"30","author":"Stamboulian","year":"2010","journal-title":"J. Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment.","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/practneurol-2013-000758","article-title":"The clinical approach to small fiber neuropathy and painful channelopathy.","volume":"14","author":"Themistocleous","year":"2014","journal-title":"Pract. Neurol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577757","article-title":"Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern.","volume":"361","author":"Tholance","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/mus.27245","article-title":"TS-HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia.","volume":"64","author":"Trevino","year":"2021","journal-title":"Muscle Nerve"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/brain\/awt053","article-title":"Small fibre pathology in patients with fibromyalgia syndrome.","volume":"136","author":"\u00dc\u00e7eyler","year":"2013","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1212\/01.wnl.0000903332.92612.04","article-title":"Response of Sjogren-related small fiber neuropathy to rituximab.","volume":"99","author":"Venkatesh","year":"2022","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/mus.27251","article-title":"Post COVID-19 vaccine small fiber neuropathy.","volume":"64","author":"Waheed","year":"2021","journal-title":"Muscle Nerve"},{"key":"B47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/mus.25738","article-title":"Acute painful autoimmune neuropathy: A variant of Guillain-Barr\u00e9 syndrome.","volume":"57","author":"Yuki","year":"2018","journal-title":"Muscle Nerve"},{"key":"B48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/CND.0000000000000355","article-title":"Clinical features and treatment response in immune-mediated small fiber neuropathy with trisulfated heparin disaccharide or fibroblast growth factor receptor 3 antibodies.","volume":"22","author":"Zeidman","year":"2021","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/CND.0000000000000423","article-title":"Immune-mediated small fiber neuropathy with trisulfated heparin disaccharide, fibroblast growth factor receptor 3, or Plexin D1 antibodies: Presentation and treatment with intravenous immunoglobulin.","volume":"24","author":"Zeidman","year":"2022","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2893-04.2004","article-title":"Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization.","volume":"24","author":"Zhuang","year":"2004","journal-title":"J. Neurosci."}],"updated-by":[{"DOI":"10.3389\/fnmol.2023.1336871","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000}}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2023.1254854\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:58:31Z","timestamp":1703210311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2023.1254854\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":50,"alternative-id":["10.3389\/fnmol.2023.1254854"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2023.1254854","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"article-number":"1254854"}}